VRTX Insider Transactions
Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
---|---|---|---|---|---|---|---|---|
2023-03-24 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 49,611 | S-Sale | D | 1,768 | 305.38 | 539,911.84 |
2023-03-17 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 53,019 | S-Sale | D | 360 | 294.52 | 106,027.20 |
2023-03-17 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 52,235 | S-Sale | D | 784 | 295.43 | 231,617.12 |
2023-03-17 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 51,995 | S-Sale | D | 240 | 296.30 | 71,112.00 |
2023-03-17 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 51,635 | S-Sale | D | 360 | 298.09 | 107,312.40 |
2023-03-17 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 51,395 | S-Sale | D | 240 | 299.58 | 71,899.20 |
2023-03-17 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 51,379 | S-Sale | D | 16 | 301.13 | 4,818.08 |
2023-03-16 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 49,532 | S-Sale | D | 2,482 | 300.54 | 745,940.28 |
2023-03-16 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 49,268 | S-Sale | D | 264 | 301.07 | 79,482.48 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 57,772 | S-Sale | D | 361 | 286.64 | 103,477.04 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 57,257 | S-Sale | D | 515 | 287.83 | 148,232.45 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 56,930 | S-Sale | D | 327 | 288.91 | 94,473.57 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 56,900 | S-Sale | D | 30 | 289.44 | 8,683.20 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 56,359 | S-Sale | D | 541 | 291.47 | 157,685.27 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 56,174 | S-Sale | D | 185 | 292.68 | 54,145.80 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 56,147 | S-Sale | D | 27 | 293.61 | 7,927.47 |
2023-03-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 56,045 | S-Sale | D | 102 | 294.94 | 30,083.88 |
2023-03-13 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 56,021 | S-Sale | D | 24 | 288.31 | 6,919.44 |
2023-03-13 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 55,061 | S-Sale | D | 420 | 292.41 | 122,812.20 |
2023-03-13 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 54,448 | S-Sale | D | 1,153 | 293.35 | 338,232.55 |
2023-03-13 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 53,733 | S-Sale | D | 715 | 294.52 | 210,581.80 |
2023-03-13 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 53,441 | S-Sale | D | 292 | 295.89 | 86,399.88 |
2023-03-13 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 53,379 | S-Sale | D | 62 | 296.77 | 18,399.74 |
2023-02-24 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 58,133 | F-InKind | D | 3,308 | 289.12 | 956,408.96 |
2023-02-24 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 57,159 | F-InKind | D | 3,308 | 289.12 | 956,408.96 |
2023-02-27 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 56,876 | S-Sale | D | 283 | 287.20 | 81,277.60 |
2023-02-27 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 56,825 | S-Sale | D | 51 | 288.33 | 14,704.83 |
2023-02-27 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 56,805 | S-Sale | D | 20 | 289.29 | 5,785.80 |
2023-02-24 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 52,014 | F-InKind | D | 3,970 | 289.12 | 1,147,806.40 |
2023-02-24 | Sachdev Amit | officer: EVP, Chief Patient Officer | 66,518 | F-InKind | D | 2,468 | 289.12 | 713,548.16 |
2023-02-24 | LEIDEN JEFFREY M | director, officer: Executive Chairman | 48,349 | F-InKind | D | 13,730 | 289.12 | 3,969,617.60 |
2023-02-24 | Kewalramani Reshma | director, officer: CEO & President | 129,969 | F-InKind | D | 9,386 | 289.12 | 2,713,680.32 |
2023-02-24 | Bozic Carmen | officer: EVP and CMO | 63,207 | F-InKind | D | 3,308 | 289.12 | 956,408.96 |
2023-02-24 | Arbuckle Stuart A | officer: EVP, COO | 61,590 | F-InKind | D | 4,714 | 289.12 | 1,362,911.68 |
2023-02-27 | Arbuckle Stuart A | officer: EVP, COO | 57,756 | S-Sale | D | 3,834 | 287.16 | 1,100,971.44 |
2023-02-27 | Arbuckle Stuart A | officer: EVP, COO | 57,356 | S-Sale | D | 400 | 287.59 | 115,036.00 |
2023-02-27 | Arbuckle Stuart A | officer: EVP, COO | 56,556 | S-Sale | D | 800 | 288.92 | 231,136.00 |
2023-02-24 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | 8,510 | F-InKind | D | 502 | 289.12 | 145,138.24 |
2023-02-27 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | 7,528 | S-Sale | D | 982 | 287.25 | 282,079.50 |
2023-02-27 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | 7,345 | S-Sale | D | 183 | 288.68 | 52,828.44 |
2023-02-27 | Ambrose Kristen | officer: SVP & Chief Accounting Officer | 7,303 | S-Sale | D | 42 | 289.63 | 12,164.46 |
2023-02-24 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 36,276 | F-InKind | D | 3,970 | 289.12 | 1,147,806.40 |
2023-02-27 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 32,640 | S-Sale | D | 3,636 | 287.23 | 1,044,368.28 |
2023-02-27 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 32,340 | S-Sale | D | 300 | 288.74 | 86,622.00 |
2023-02-27 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 32,038 | S-Sale | D | 302 | 289.60 | 87,459.20 |
2023-02-22 | Arbuckle Stuart A | officer: EVP, COO | 68,576 | S-Sale | D | 129 | 291.84 | 37,647.36 |
2023-02-22 | Arbuckle Stuart A | officer: EVP, COO | 68,276 | S-Sale | D | 300 | 292.86 | 87,858.00 |
2023-02-22 | Arbuckle Stuart A | officer: EVP, COO | 66,898 | S-Sale | D | 1,378 | 294.29 | 405,531.62 |
2023-02-22 | Arbuckle Stuart A | officer: EVP, COO | 66,504 | S-Sale | D | 394 | 295.38 | 116,379.72 |
2023-02-22 | Arbuckle Stuart A | officer: EVP, COO | 66,304 | S-Sale | D | 200 | 296.31 | 59,262.00 |
2023-02-17 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 61,441 | F-InKind | D | 3,750 | 292.85 | 1,098,187.50 |
2023-02-17 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 60,947 | F-InKind | D | 4,498 | 292.85 | 1,317,239.30 |
2023-02-21 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 60,943 | S-Sale | D | 4 | 291.01 | 1,164.04 |
2023-02-21 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 60,798 | S-Sale | D | 145 | 292.85 | 42,463.25 |
2023-02-21 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 60,591 | S-Sale | D | 207 | 293.83 | 60,822.81 |
2023-02-21 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 60,467 | S-Sale | D | 124 | 294.77 | 36,551.48 |
2023-02-17 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 55,984 | F-InKind | D | 3,750 | 292.85 | 1,098,187.50 |
2023-02-17 | Sachdev Amit | officer: EVP, Chief Patient Officer | 68,986 | F-InKind | D | 3,498 | 292.85 | 1,024,389.30 |
2023-02-17 | Kewalramani Reshma | director, officer: CEO & President | 139,355 | F-InKind | D | 9,359 | 292.85 | 2,740,783.15 |
2023-02-17 | Bozic Carmen | officer: EVP and CMO | 66,515 | F-InKind | D | 3,750 | 292.85 | 1,098,187.50 |
2023-02-17 | Arbuckle Stuart A | officer: EVP, COO | 71,107 | F-InKind | D | 4,498 | 292.85 | 1,317,239.30 |
2023-02-21 | Arbuckle Stuart A | officer: EVP, COO | 71,086 | S-Sale | D | 21 | 291.01 | 6,111.21 |
2023-02-21 | Arbuckle Stuart A | officer: EVP, COO | 70,541 | S-Sale | D | 545 | 292.77 | 159,559.65 |
2023-02-21 | Arbuckle Stuart A | officer: EVP, COO | 69,441 | S-Sale | D | 1,100 | 293.74 | 323,114.00 |
2023-02-21 | Arbuckle Stuart A | officer: EVP, COO | 68,705 | S-Sale | D | 736 | 294.58 | 216,810.88 |
2023-02-17 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 44,248 | F-InKind | D | 3,750 | 292.85 | 1,098,187.50 |
2023-02-21 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 44,212 | S-Sale | D | 36 | 291.01 | 10,476.36 |
2023-02-21 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 42,989 | S-Sale | D | 1,223 | 292.76 | 358,045.48 |
2023-02-21 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 41,146 | S-Sale | D | 1,843 | 294.03 | 541,897.29 |
2023-02-21 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 40,246 | S-Sale | D | 900 | 294.73 | 265,257.00 |
2023-02-14 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,694 | S-Sale | D | 71 | 295.89 | 21,008.19 |
2023-02-14 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,674 | S-Sale | D | 20 | 296.48 | 5,929.60 |
2023-02-14 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,631 | S-Sale | D | 43 | 297.98 | 12,813.14 |
2023-02-14 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,496 | S-Sale | D | 135 | 299.60 | 40,446.00 |
2023-02-14 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,445 | S-Sale | D | 51 | 300.58 | 15,329.58 |
2023-02-14 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 60,013 | S-Sale | D | 1,902 | 300.29 | 571,151.58 |
2023-02-14 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 59,734 | S-Sale | D | 279 | 301.11 | 84,009.69 |
2023-02-14 | Arbuckle Stuart A | officer: EVP, COO | 81,203 | S-Sale | D | 800 | 295.84 | 236,672.00 |
2023-02-14 | Arbuckle Stuart A | officer: EVP, COO | 80,302 | S-Sale | D | 901 | 296.85 | 267,461.85 |
2023-02-14 | Arbuckle Stuart A | officer: EVP, COO | 79,742 | S-Sale | D | 560 | 298.14 | 166,958.40 |
2023-02-14 | Arbuckle Stuart A | officer: EVP, COO | 77,739 | S-Sale | D | 2,003 | 299.13 | 599,157.39 |
2023-02-14 | Arbuckle Stuart A | officer: EVP, COO | 76,005 | S-Sale | D | 1,734 | 300.09 | 520,356.06 |
2023-02-14 | Arbuckle Stuart A | officer: EVP, COO | 75,605 | S-Sale | D | 400 | 300.89 | 120,356.00 |
2023-02-14 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 53,596 | S-Sale | D | 800 | 295.79 | 236,632.00 |
2023-02-14 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 52,754 | S-Sale | D | 842 | 296.85 | 249,947.70 |
2023-02-14 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 52,359 | S-Sale | D | 395 | 297.97 | 117,698.15 |
2023-02-14 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 50,194 | S-Sale | D | 2,165 | 299.08 | 647,508.20 |
2023-02-14 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 48,306 | S-Sale | D | 1,888 | 300.11 | 566,607.68 |
2023-02-14 | ALTSHULER DAVID | officer: EVP, Global Research and CSO | 47,998 | S-Sale | D | 308 | 301.02 | 92,714.16 |
2023-02-10 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 70,183 | F-InKind | D | 2,707 | 294.33 | 796,751.31 |
2023-02-13 | WAGNER CHARLES F JR | officer: EVP & Chief Financial Officer | 65,191 | F-InKind | D | 4,992 | 298.26 | 1,488,913.92 |
2023-02-10 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 69,035 | F-InKind | D | 1,377 | 294.33 | 405,292.41 |
2023-02-13 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 66,040 | F-InKind | D | 2,995 | 298.26 | 893,288.70 |
2023-02-13 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 66,038 | S-Sale | D | 2 | 295.84 | 591.68 |
2023-02-13 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,960 | S-Sale | D | 78 | 298.11 | 23,252.58 |
2023-02-13 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,840 | S-Sale | D | 120 | 298.98 | 35,877.60 |
2023-02-13 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,776 | S-Sale | D | 64 | 299.88 | 19,192.32 |
2023-02-13 | Tatsis Ourania | officer: EVP, Chief Reg. & Quality Off. | 65,765 | S-Sale | D | 11 | 300.79 | 3,308.69 |
2023-02-10 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 66,368 | F-InKind | D | 902 | 294.33 | 265,485.66 |
2023-02-13 | Sanna Bastiano | officer: EVP, Cell & Genetic Therapies | 62,028 | F-InKind | D | 4,340 | 298.26 | 1,294,448.40 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.